# Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

> **NCT02397096** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 673 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Doravirine, Tenofovir, Lamivudine
- **DRUG:** Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
- **DRUG:** Baseline regimen of cobicistat-boosted elvitegravir
- **DRUG:** Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
- **DRUG:** Baseline regimen of two nucleoside reverse transcriptase inhibitors

## Key facts

- **NCT ID:** NCT02397096
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-09
- **Primary completion:** 2018-02-22
- **Final completion:** 2023-09-05
- **Target enrollment:** 673 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397096, "Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02397096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*